Nuvamid Alternatives & Competitors
12 companies similar to Nuvamid — A clinical stage biotech focused on the research and use of nucleotides, as ther...
Companies similar to Nuvamid
Lumos Pharma
Transforming Lives with Rare Focus
Austin, United States
Biodexa Pharmaceuticals PLC
Advancing Medicines for a Brighter Future
Cardiff, United Kingdom
Ractigen Therapeutics
Turn on genes and turn off diseases
Suzhou, China
Pharvaris
Pioneering science for patient choice
Zug, Switzerland
Rival Readout
Competing with Nuvamid? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Orca Bio
Transforming allogeneic cell therapy for patients with cancer and autoimmune diseases.
Menlo Park, United States
Sitryx
Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therap...
Oxford, United Kingdom
Emmaus Life Sciences, Inc
Improving the lives of people with rare disease.
Torrance, United States
ImmunoMet Therapeutics, Inc.
Targeting Metabolic Reprogramming in Fibrosis and Oncology
Ultragenyx
Going Beyond Every Day
Novato, United States
X4 Pharmaceuticals
Enabling a better future for people with rare immune disorders
Boston, United States
Dyne Therapeutics
Advancing life-transforming therapies for serious muscle diseases
Waltham, United States
Vico Therapeutics
Our mission is simple… bring innovative RNA modulating therapies to patients with severe,...
Leiden, The Netherlands
About Nuvamid
Nuvamid, founded in 2019 and headquartered in Switzerland, is a clinical stage biotech with a focus on the research and utilization of nucleotides as therapeutics for rare diseases. Known for their slogan, "A clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare diseases," thei...
Research and development of nucleotide-based therapies, Clinical stage trials for rare blood diseases, Collaboration with academic and research institutions
Patients with rare blood diseases, Healthcare providers specializing in rare diseases, Pharmaceutical and biotech partners
Clinical Stage Biotech, Nucleotide Therapeutics, Rare Diseases, Endogenous Molecules, Breakthrough Therapeutics, Rare Blood Diseases, Blood Cell Disorders, NUV01, Phase 2 Clinical Trials, NAD Metabolism, NAD Metabolism Modulators, Preclinical Data, Immune Disorders, Research Collaborations, Biopharmaceutical Development
B2B, B2D
Licensing, Product Sales, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Nuvamid: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Nuvamid on 4 Mar 2026. The 12 companies listed here were last checked between 12 Sep 2024 and 10 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
